Articles15 August 1993
    Author, Article and Disclosure Information

    To determine the effect of trimethoprim-sulfamethoxazole (Tmp-Smx) on serum potassium concentration.


    Retrospective cohort study.


    An urban teaching hospital.


    Fifty-one persons hospitalized for symptomatic infection with human immunodeficiency virus (HIV). Twenty-five patients who were taking high-dose Tmp-Smx (trimethoprim 20 mg/kg per day; sulfamethoxazole, 100 mg/kg per day) for Pneumocystis carinii pneumonia were the study group. Twenty-six patients who had not received the drug were the control group. Patients who received potassium supplements, those taking medications known to alter potassium homeostasis or renal function, or those with a serum creatinine level more than 186 mol/L were excluded.

    Measurements and Main Results:

    Serum potassium concentration in the study group was 4.1 0.1 mmol/L (mean SE) and increased by 1.1 mmol/L (CI, 0.8 to 1.5 mmol/L) (P < 0.0001) 9.8 0.5 days after starting Tmp-Smx therapy. Patients followed longitudinally showed a progressive increase in serum potassium levels during therapy and a progressive decline after discontinuing Tmp-Smx. Blood urea nitrogen and serum creatinine levels increased mildly from 4.3 0.5 mmol/L and 85 6 mol/L to 6.4 0.7 mmol/L and 113 8 mol/L, respectively. The serum potassium level in the control group was 4.3 0.1 mmol/L and remained unchanged during hospitalization.


    High-dose Tmp-Smx therapy used for the treatment of P. carinii pneumonia in HIV-infected patients leads to an increase in the serum potassium concentration and may result in life-threatening hyperkalemia. Patients receiving high doses of Tmp-Smx require close monitoring of their serum potassium concentration, particularly 7 to 10 days after the start of therapy.


    • 1. Seney FD Jr, Burns DK, Silva FG. Acquired immunodeficiency syndrome and the kidney. Am J Kidney Dis. 1990; 16:1-13. Google Scholar
    • 2. Vaziri ND, Barbari A, Licorish K, Cesario T, Gupta S. Spectrum of renal abnormalities in acquired immune-deficiency syndrome. J Natl Med Assoc. 1985; 77:369-75. Google Scholar
    • 3. Greene LW, Cole W, Greene JB, Levy B, Louie E, Raphael B, et al. Adrenal insufficiency as a complication of the acquired immunodeficiency syndrome. Ann Intern Med. 1984; 101:497-8. Google Scholar
    • 4. Membreno L, Irony I, Dere W, Klein R, Biglieri EG, Cobb E. Adrenocortical function in acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1987; 65:482-7. Google Scholar
    • 5. Kalin MF, Poretsky L, Seres DS, Zumoff B. Hyporeninemic hypoaldosteronism associated with acquired immune deficiency syndrome. Am J Med. 1987; 82:1035-8. Google Scholar
    • 6. Lachaal M, Venuto RC. Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine. Am J Med. 1989; 87:260-3. Google Scholar
    • 7. Guy RJ, Turberg Y, Davidson RN, Finnerty G, MacGregor GA, Wise PH. Mineralocorticoid deficiency in HIV infection. Br Med J. 1989; 298:496-7. Google Scholar
    • 8. Murphy CF, Ratnavel RC, Davidson AC. Mineralocorticoid deficiency in HIV infection. Br Med J. 1989; 298:1181. Google Scholar
    • 9. Schoenfeld P, Feduska NJ. Acquired immunodeficiency syndrome and renal disease: report of the National Kidney Foundation-National Institutes of Health Task Force in AIDS and Kidney Disease. Am J Kidney Dis. 1990; 16:14-25. Google Scholar
    • 10. Appel GB, Neu HC. The nephrotoxicity of antimicrobial agents (third of 3 parts). N Engl J Med. 1977; 296:784-87. Google Scholar
    • 11. Linton AL, Clark WF, Dreidger AA, Turnbull DI, Lindsay RM. Acute interstitial nephritis due to drugs. Ann Intern Med. 1980; 93: 735-41. Google Scholar
    • 12. Smith EJ, Light JA, Filo RS, Yum MN. Interstitial nephritis caused by trimethoprim-sulfamethoxazole in renal transplant recipients. JAMA. 1980; 244:360-1. Google Scholar
    • 13. Revert L, Montoliu J. Acute interstitial nephritis. Semin Nephrol. 1988; 8:82-8. Google Scholar
    • 14. Cryst C, Hammar SP. Acute granulomatous interstitial nephritis due to co-trimoxazole. Am J Nephrol. 1988; 8:483-8. Google Scholar
    • 15. Richmond JM, Whitworth JA, Fairly KF, Kincaid-Smith P. Co-trimoxazole nephrotoxicity. Lancet. 1979; 1:493. Google Scholar
    • 16. Shouval D, Ligumsky M, Ben-Ishay D. Effect of co-trimoxazole on normal creatinine clearance. Lancet. 1978; 1:244-5. Google Scholar
    • 17. Berglund F, Killander J, Pompeius R. Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. J Urol. 1975; 114:802-8. Google Scholar
    • 18. Lawson DH, Jick H. Adverse reactions to co-trimoxazole in hospitalized medical patients. Am J Med Sci. 1978; 275:53-7. Google Scholar
    • 19. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis. 1982; 4:426-8. Google Scholar
    • 20. Lawson DH, Paice BJ. Adverse reactions to trimethoprim-sulfamethoxazole. Rev Infect Dis. 1982; 4:429-33. Google Scholar
    • 21. Jaffe HS, Abrams DI, Amman AJ, Lewis BJ, Golden JA. Complications of co-trimoxazole in treatment of aids-associated Pneumocystis carinii pneumonia in homosexual men. Lancet. 1983; 2:1109-11. Google Scholar
    • 22. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1984; 100:495-9. Google Scholar
    • 23. Medina I, Mills J, Leoung G, Hopewell PC, Lee B, Modin G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990; 323:776-82. Google Scholar
    • 24. Choi MJ, Fernandez PC, Patnaik A, Coupaye-Gerard B, D'Andrea D, Szerlip H, et al. Hyperkalemia and renal salt wasting due to the K sparing diuretic effects of trimethoprim. J Am Soc Nephrol. 1992; 3:325. Google Scholar
    • 25. Velazquez H, Perazella M, Wright FS, Ellison DH. Hyperkalemia and AIDS: trimethoprim inhibits potassium secretion by the renal distal tubule. J Am Soc Nephrol. 1992; 3:322. Google Scholar